Casandra A. Murphy

Associate

EDUCATION
  • Gettysburg College
    B.A.
  • Widener University School of Law
    J.D.
ADMISSIONS
  • Pennsylvania
  • New Jersey
  • USDC, Eastern District of Pennsylvania
PDF

Casandra A. Murphy’s practice at Kessler Topaz Meltzer & Check, L.L.P. is focused on the areas of antitrust and complex consumer litigation. Casandra is presently litigating a number of class action lawsuits against large pharmaceutical manufacturers in antitrust cases alleging improper reverse payments and generic suppression schemes.

Casandra also served as a special assistant attorney general to several states in litigation involving the sales and marketing practices of major pharmaceutical companies.  These cases led to important injunctive relief and significant monetary recovery for those states.

Examples of Casandra’s recent notable cases include In re Flonase Antitrust Litigation ($150 million settlement on behalf of direct purchasers); and In re Wellbutrin SR Antitrust Litigation ($21.5 million settlement on behalf of end-payors).

Experience
Representative Outcomes
  • Kessler Topaz served as a lead counsel on behalf of a class of direct purchaser plaintiffs in an antitrust action brought pursuant to Section 4 of the Clayton Act, 15 U.S.C. § 15, alleging, among other things, that defendant GlaxoSmithKline (GSK) violated Section 2 of the Sherman Act, 15 U.S.C. § 2, by engaging in “sham” petitioning of a government agency. 

    Specifically, the Direct Purchasers alleged that GSK unlawfully abused the citizen petition process contained in Section 505(j) of the Federal Food, Drug, and Cosmetic Act and thus delayed the introduction of less expensive generic versions of Flonase, a highly popular allergy drug, causing injury to the Direct Purchaser Class.  Throughout the course of the four year litigation, Plaintiffs defeated two motions for summary judgment, succeeded in having a class certified and conducted extensive discovery.  After lengthy negotiations and shortly before trial, the action settled for $150 million.

Publication

“Fighting the high cost of healthcare,” Trial Magazine (October 2007)